Amundi’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Amundi’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,060	Closed	-$20.1K	–	2092
2023 Q3	$20.1K	Sell	1,060 -3,329	-76%	-$84.5K	﹤0.01%	1934
2023 Q2	$124K	Hold	4,389	–	–	﹤0.01%	1723
2023 Q1	$77.1K	Hold	4,389	–	–	﹤0.01%	1807
2022 Q4	$92.7K	Sell	4,389 -363	-8%	-$7.81K	﹤0.01%	1623
2022 Q3	$109K	Hold	4,752	–	–	﹤0.01%	1542
2022 Q2	$143K	Buy	+4,752	New	+$126K	﹤0.01%	1398

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Amundi's ZNTL Position: Q4 2023 in Review

Amundi sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2023, closing a stake of 1,060 shares — an estimated $20.1K sold.

Amundi first reported a position in ZNTL in Q2 2022 and held it in 6 quarters. The position peaked at $143K in Q2 2022. 120 funds tracked by Wall St. Rank hold ZNTL as of Q4 2023.

Amundi reported no remaining Zentalis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Amundi sold 1,060 Zentalis Pharmaceuticals shares in Q4 2023, an estimated $20.1K.
Amundi first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 6 quarters.
Amundi's Zentalis Pharmaceuticals position peaked at $143K in Q2 2022.
120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2023.

Based on Amundi's 13F filing for Q4 2023, filed 14 Feb 2024.